Were Analysts Bullish Alcobra Ltd. (NASDAQ:ADHD) This Week?

December 7, 2017 - By Michael Collier

 Were Analysts Bullish Alcobra Ltd. (NASDAQ:ADHD) This Week?

Alcobra Ltd. (NASDAQ:ADHD) Ratings Coverage

Among 7 analysts covering Alcobra (NASDAQ:ADHD), 2 have Buy rating, 1 Sell and 4 Hold. Therefore 29% are positive. Alcobra had 19 analyst reports since August 9, 2015 according to SRatingsIntel. Jefferies downgraded the stock to “Hold” rating in Wednesday, January 18 report. The stock of Alcobra Ltd. (NASDAQ:ADHD) earned “Buy” rating by TH Capital on Friday, August 14. The firm has “Buy” rating by Roth Capital given on Thursday, February 4. The company was upgraded on Monday, October 9 by WBB Securities. Barclays Capital downgraded the shares of ADHD in report on Friday, October 28 to “Underweight” rating. Cantor Fitzgerald downgraded the shares of ADHD in report on Thursday, September 29 to “Hold” rating. Roth Capital maintained Alcobra Ltd. (NASDAQ:ADHD) on Tuesday, June 21 with “Buy” rating. The company was maintained on Sunday, August 9 by WBB Securities. The stock of Alcobra Ltd. (NASDAQ:ADHD) earned “Perform” rating by Oppenheimer on Thursday, September 29. The rating was maintained by Jefferies on Monday, June 12 with “Hold”. Below is a list of Alcobra Ltd. (NASDAQ:ADHD) latest ratings and price target changes.

09/10/2017 Broker: WBB Securities Old Rating: Hold New Rating: Speculative Buy New Target: $2 Upgrade
29/09/2017 Broker: Roth Capital Rating: Hold New Target: $1.0 Downgrade
11/08/2017 Broker: Roth Capital Rating: Buy New Target: $4.0000 Maintain
12/06/2017 Broker: Jefferies Rating: Hold New Target: $1.2500 Maintain

The stock increased 4.29% or $0.42 during the last trading session, reaching $10.22. About 1.11M shares traded. Alcobra Ltd. (NASDAQ:ADHD) has declined 74.73% since December 7, 2016 and is downtrending. It has underperformed by 91.43% the S&P500.

More notable recent Alcobra Ltd. (NASDAQ:ADHD) news were published by: Globenewswire.com which released: “Arcturus Therapeutics Announces Presentations at Conferences in November” on October 26, 2017, also Globenewswire.com with their article: “Arcturus Therapeutics to Host Key Opinion Leader Call on Advances in Delivery …” published on November 02, 2017, Globenewswire.com published: “Arcturus Therapeutics and Synthetic Genomics Announce Strategic Alliance to …” on October 31, 2017. More interesting news about Alcobra Ltd. (NASDAQ:ADHD) were released by: Globenewswire.com and their article: “Alcobra Ltd. and Arcturus Therapeutics, Inc. Agree to Merge” published on September 27, 2017 as well as Seekingalpha.com‘s news article titled: “Alcobra to merge with Arcturus Therapeutics in all-stock deal; shares ahead 15 …” with publication date: September 28, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.